visnagin has been researched along with Cardiotoxicity in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Asnani, A; Chen, HH; Chi, A; Cornella-Taracido, I; Johns, DG; Liu, Y; Peterson, RT; Sosnovik, DE; Vohra, A; Wang, H; Wang, Y; Zheng, B | 1 |
1 other study(ies) available for visnagin and Cardiotoxicity
| Article | Year |
|---|---|
Highly potent visnagin derivatives inhibit Cyp1 and prevent doxorubicin cardiotoxicity.
Topics: Animals; Apoptosis; Cardiotoxicity; Cell Line; Cytochrome P450 Family 1; Doxorubicin; Heart; Khellin; Male; Mice; Mice, Inbred C57BL; Models, Animal; Myocytes, Cardiac; Structure-Activity Relationship; Xenobiotics; Zebrafish | 2018 |